The $328M peptide gray market — what it is, who's behind it, and what happens next
“In 2025, $328 million of peptide material was imported into the US outside the licensed pharmaceutical channel. That isn't bootleg — that's an entire category.”
The number
In 2025, aggregate peptide imports from Chinese manufacturers to US buyers hit $328 million, per trade-press estimates tracked by multiple industry outlets. That's a three-year doubling since the FDA's 2023 restrictions pushed compounding pharmacies out of several key peptide lines.
Three hundred and twenty-eight million dollars of peptide material flowing into a single country through the "research chemical" channel.
What's actually happening
The FDA's November 2023 decision was narrow on paper — it tightened restrictions on which peptides compounding pharmacies could produce. But demand was already outrunning supply. Clinics that couldn't get BPC-157 from licensed compounders turned to research-peptide vendors. Biohackers followed. Creators on X amplified the arbitrage.
By 2025, the entire stack had re-routed: API from Chinese and Indian manufacturers, purity testing in Czech and US labs, fulfilment through Delaware LLCs, payment in card-on-file (not crypto-only any more), delivery by USPS Priority.
Why it matters for you
- Supply is not going away. The US market is bigger than it was before the FDA tightened. The distribution just shifted.
- Purity variance is real. Some research-peptide vendors publish per-batch COAs from Janoshik / Finnrick / Freedom Diagnostics. Some don't. See our quality tester directory to know which lab is behind which vendor.
- The regulatory shoe may drop again. RFK Jr. restored 14 peptides to legal compounding in February 2026 — easing pressure — but individual peptides could be re-restricted at any time. Our regulation tracker follows each event.
Where this goes
Three things happen from here:
- Telehealth consolidation. Hims, Ro and GobyMeds are eating the GLP-1 gray market by operating within the prescription channel.
- Compounding restoration. RFK Jr's Feb 2026 HHS order signals further softening on BPC-157, TB-500 and growth-hormone secretagogues.
- More vendor competition. More vendors → better prices for buyers. That's where we come in.
If you're shopping
Run the BPC-157 price comparison — we track six vendors, three of them with per-batch COAs.